An Ad5 prime–MVA boost strategy targeting the tuberculosis antigen Ag85A elicited significantly enhanced CD4+ and CD8+ T cell responses in mice compared to homologous Ad5 or MVA regimens (24). This evidence concerns the gene CD4 and tuberculosis.